Atlas FDA

therascreen EGFR RGQ PCR Kit

FDA premarket approval P120022/S022 · decided 2021-07-07

Approval details

PMA number
P120022
Supplement
S022
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
therascreen EGFR RGQ PCR Kit
Generic name
Somatic gene mutation detection system
Applicant
QIAGEN GmbH
Date received
2020-10-23
Decision date
2021-07-07
Days to decision
257 days
Decision code
APPR
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Hilden
Statement
Approval for incorporation of a lower boundary for the therascreen EGFR RGQ PCR assay Ct cutoff range and an update to the software and handbook to address this change.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
QIAstat-Dx BCID GPF Plus AMR Panel (K254194)QIAGEN GmbH2026-08-06
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K254032)QIAGEN GmbH2026-03-09
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K252329)QIAGEN GmbH2025-10-22
QIAstat-Dx Respiratory Panel Plus; QIAstat-Dx Respiratory Panel Mini (K250080)QIAGEN GmbH2025-08-27
QIAstat-Dx GI Panel 2 Mini B (K250324)QIAGEN GmbH2025-02-28
QIAstat-Dx GI Panel 2 Mini B&V (K243813)QIAGEN GmbH2025-01-08
QIAstat-Dx Meningitis/Encephalitis (ME) Panel (K242256)QIAGEN GmbH2024-10-29
QIAstat-Dx Respiratory Panel Mini (K242353)QIAGEN GmbH2024-10-25